Some of the most promising medical ideas hide in plain sight. Researchers at the University of Manchester think one of the best early-warning systems for breast cancer may be something produced by the breast itself: breast milk. A team led by Dr. Niki Flaum, a consultant oncologist at the Christie NHS Foundation Trust, is investigating whether fragments of circulating tumor DNA found in breast milk could reveal the disease earlier than a blood test or a scan. The work, reported by the Press Association on Oct. 3, opens a door that scientists say has been ignored for far too long.
“We know surprisingly little about the genetic changes to breast milk, as this bio-fluid has been remarkably under-researched until now,” Flaum said. She is blunt about the need: “There is an urgent need to find better, more reliable ways to detect breast cancer in women during and after pregnancy.”
A dangerous blind spot
Here is the paradox the Manchester team is trying to solve. Breastfeeding is linked to a lower lifetime risk of breast cancer, which is genuinely good news. But during pregnancy and in the months after giving birth, a woman’s risk is actually higher, and that is exactly when detection is hardest. Breast imaging during pregnancy and lactation is often unreliable because the tissue changes so much. The result is that pregnancy-associated breast cancer is more likely to be diagnosed at a later stage, after it has already spread, and survival outcomes are significantly worse than for women of the same age who have not recently given birth.
The numbers sharpen the point. Pregnancy-related breast cancer is thought to affect roughly one in 3,000 pregnancies, but the risk can climb as high as one in 50 for women carrying a faulty BRCA gene. Breast cancer remains the most common cause of cancer-related death among women aged 35 to 64 in the UK. For younger women with inherited genetic faults, a reliable screening tool during those years would be life-changing.
What the science already suggests
Flaum’s team is not starting from zero. Published research on breast milk as a source of tumor DNA has already shown striking results: in one study, researchers identified circulating tumor DNA in the affected breast of every evaluable breast cancer patient they tested, and none in the unaffected breast. More remarkable still, two patients had frozen breast milk samples from an earlier pregnancy. In one case, a sample collected 18 months before the woman’s diagnosis carried the same cancer-linked mutation found in her tumor. In another, a mutation appeared in breast milk at earlier time points while ultrasound did not find the tumor until the 17th month after childbirth.
The researchers’ conclusion was bold: breast milk appears to be a superior source of tumor DNA compared with blood plasma for early-stage breast cancer, and it could be adapted for early detection “in a setting compatible with routine clinical practice.” That phrase matters. A screening method only helps if women can actually use it, and a non-invasive sample collected at home clears a bar that mammograms and biopsies cannot.
Where it goes from here
Flaum is careful about the timeline. Her team first needs reliable methods for detecting cancer-related DNA in breast milk, and only then can future research test whether the approach works as a screening tool for women with breast cancer or those at high risk. This is early-stage science, and early-stage science sometimes disappoints. But the direction of travel is unmistakable: medicine is getting better at finding cancer before it announces itself, from Biogen’s durable results for lupus skin disease to new research on boosting brain blood flow in people at risk of Alzheimer’s. Each of these studies chases the same prize: intervene earlier, and outcomes improve.
For women reading this today, the practical takeaway is straightforward, and it does not require waiting for a breakthrough. If you are pregnant, recently gave birth, or breastfeeding and you notice a lump, thickening, or change in your breast, get it checked promptly rather than assuming it is a pregnancy change. Push for follow-up if something feels wrong, because the hardest part of this disease in young mothers is delay, not biology. Knowing your family history and your genetic risk matters too. The Manchester research is about the future, but vigilance is the screening tool that already exists.
There is also a quieter point worth making. Women’s bodies have been under-researched in medicine for decades, and breast milk may be one of the most under-studied fluids of all. That a team in Manchester is now treating it as a window into what is happening inside the breast, in Flaum’s words, feels like a correction long overdue. If the science holds, a few milliliters of milk could one day do what a mammogram cannot: catch cancer in the women who are hardest to screen, at the moment when catching it matters most. That is a future worth rooting for.
